Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 15 Aug 2017 |
| Genmab Announces Financial Results for the First Half of 2017 | 9 Aug 2017 |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2017 | 18 Jul 2017 |
| Articles of Association for Genmab A/S | 28 Jun 2017 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 27 Jun 2017 |